SCHEMBL25409705

SCHEMBL25409705

O=C(OCc1ccccc1)c1ccc2cnc(Cl)cc2c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.51
▸ TDP1 Q9NUW8 4/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ SLC6A2 P23975 1/20 0.51
▸ SLC6A3 Q01959 1/20 0.51
▸ ALDH1A1 P00352 5/20 0.49
▸ RAB9A P51151 5/20 0.49
▸ MAPT P10636 4/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ NPC1 O15118 3/20 0.49
▸ POLB P06746 1/20 0.47
▸ HPGD P15428 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.45
▸ HTT P42858 2/20 0.45
▸ JMJD6 Q6NYC1 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ EGLN1 Q9GZT9 1/20 0.43
▸ GAA P10253 1/20 0.42
▸ P2RX7 Q99572 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31435413 1.00 LMNA (0.51) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL25408783 0.86 TDP1 (0.53) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL6002245 0.82 KMT2A (0.70) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL4130439 0.81 LMNA (0.60) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL17559333 0.80 TDP1 (0.58) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL25407262 0.79 TDP1 (0.54) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL9374743 0.79 TDP1 (0.66) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL2706461 0.79 KMT2A (0.66) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL21511088 0.78 LMNA (0.69) LMNATDP1KMT2ASLC6A2SLC6A3
SCHEMBL6001946 0.78 KMT2A (0.64) LMNATDP1KMT2ASLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179103-A1 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS RECLUDIX PHARMA, INC. 2025-06-05 — — US disclosed
CN-119301127-A 6-Oxo-decahydro pyrrolo [1,2-a ] [1,5] diazocine and 6-oxo-decahydro-4H-pyrrolo [2,1-d ] [1,5] thiaazacine derivatives as modulators of STAT3 and STAT6 for the treatment of cancer and inflammatory conditions 瑞克鲁迪克斯制药股份有限公司 2025-01-10 — — CN disclosed
WO-2023164680-A1 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS RECLUDIX PHARMA, INC. (US) 2023-08-31 — — WO disclosed
WO-2023164680-A1 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS RECLUDIX PHARMA, INC. (US) 2023-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179103-A1 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS STAT6, STAT3, STAT1 LMNA 4860/4885TDP1 2910/4885KMT2A 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback